Sixty-ninth Legislative Assembly of North Dakota

HOUSE BILL NO. 1543

Introduced by

8

9

10

11

13

Representatives Meier, K. Anderson, Bolinske, Dobervich, Frelich, Heinert, Holle, Rohr, Weisz

Senators Cleary, Dever, Hogan

- 1 A BILL for an Act to provide for a legislative management study regarding prescription drug
- 2 pricing and the maximum fair price as determined by the federal government.

3 BE IT ENACTED BY THE LEGISLATIVE ASSEMBLY OF NORTH DAKOTA:

4 SECTION 1. LEGISLATIVE MANAGEMENT STUDY - PRESCRIPTION DRUG PRICING.

- During the 2025-26 interim, the legislative management shall consider studying prescription drug pricing or the maximum fair price for a drug as published by the secretary of the United States department of health and human services.
 - The study must include consideration of federal drug price negotiations under the Federal Inflation Reduction Act of 2022 [Pub. L. 117-169; 26 U.S.C. 55 et seq.] and overlap with current drugs paid for by the public employees retirement system to determine usage and potential cost-savings to the state and consumers.
- 12 3. The study must include input from:
 - a. The public employees retirement system;
- b. The insurance commissioner;
- 15 c. The state board of pharmacy; and
- d. Other stakeholders.
- The legislative management shall report its findings and recommendations, together
 with any legislation necessary to implement the recommendations, to the seventieth
 legislative assembly.